Innovative science

Technology

Global network

CbsBioscience retains enormous clinical and experimental data through establishment of strong global clinical research network by conducting collaborative research in 7 types of cancers

  • Domestic: KCSG 102 hospitals, K-MASTER 53 hospitals, and KCBC 13 hospitals
  • International: 2 countries (Italy, Japan)

KCBC
Korea Cancer Biomarker Consortium

Participated Hospitals : 13

  • New Health Technology : Liver Cancer Prognostic test
  • OncoHepaTest®
  • Nexavar® CDx clinical trial
  • Biomarker to predict TACE response

KCSG
Korean Cancer Study Group

Participated Hospitals : 102

  • Head and Neck Cancer
  • Small Cell Lung Cancer
  • Sarcomatoid Carcinoma
  • Salivary Gland Tumor
  • Will Expand to other Cancer Types

K-MASTER
Cancer Precision Medicine Diagnosis and Treatment Enterprise

Participated Hospitals : 53

  • Triple-Negative Breast Cancer patients’ clinico-genomic data analysis
  • Expand to all cancer types, Big data based tailored treatment analysis

Italy I.R.C.C.S

  • MOU signed for biomarker development
  • nCounter based Nexavar® biomarker validation
  • Liver Cancer prognostic test OncoHepa validation on Italian cohort

Japan WHMU

  • MOU signed for biomarker development
  • Completion of liver cancer prognostic test OncoHepa validation on Japanese cohort
  • nCounter based Nexavar® biomarker validation

Other Partners

  • Nanostring
  • BMS